124 related articles for article (PubMed ID: 3117675)
1. Policy and research in end-stage renal disease.
Jones KR
Image J Nurs Sch; 1987; 19(3):126-9. PubMed ID: 3117675
[No Abstract] [Full Text] [Related]
2. Why we need the option of more dialysis.
Hodge MH
Nephrol News Issues; 2006 Oct; 20(11):76, 78-9. PubMed ID: 17039973
[No Abstract] [Full Text] [Related]
3. Is HCFA's reimbursement policy controlling quality of care for end-stage renal disease patients?
Lockridge RS; McKinney JK
ASAIO J; 2001; 47(5):466-8. PubMed ID: 11575817
[No Abstract] [Full Text] [Related]
4. Bundling, and what is important for patients.
Eilers D; LeBeau K
Nephrol News Issues; 2009 Dec; 23(13):11. PubMed ID: 20050433
[No Abstract] [Full Text] [Related]
5. HCFA: failing to acknowledge the unique characteristics of the ESRD patient.
Kanter A; Nidetz M
Nephrol News Issues; 1990 Feb; 4(2):23-6, 31. PubMed ID: 2320135
[No Abstract] [Full Text] [Related]
6. Practice patterns, case mix, Medicare payment policy, and dialysis facility costs.
Hirth RA; Held PJ; Orzol SM; Dor A
Health Serv Res; 1999 Feb; 33(6):1567-92. PubMed ID: 10029498
[TBL] [Abstract][Full Text] [Related]
7. Important legal, regulatory issues impacting renal care in 2008.
Riley J; Pristave R
Nephrol News Issues; 2008 Dec; 22(13):48-9. PubMed ID: 19149317
[No Abstract] [Full Text] [Related]
8. How dialysis is paid for: what the dialysis medical director should know, and why.
Deoreo PB
Semin Dial; 2008; 21(1):58-62. PubMed ID: 18086259
[TBL] [Abstract][Full Text] [Related]
9. End stage renal disease and Medicare.
Greer JW
Health Care Financ Rev; 2003; 24(4):1-5. PubMed ID: 14628396
[No Abstract] [Full Text] [Related]
10. Renal Dialysis and its Financing.
Borelli M; Paul DP; Skiba M
Hosp Top; 2016; 94(2):33-8. PubMed ID: 27315562
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Evidence behind Policy Mandates in US Dialysis Care.
Erickson KF; Winkelmayer WC
J Am Soc Nephrol; 2018 Dec; 29(12):2777-2779. PubMed ID: 30389727
[No Abstract] [Full Text] [Related]
12. Tackling pay-for-performance: current and future challenges.
Bhat P; Bhat JG
Nephrol News Issues; 2012 Jan; 26(1):27-9. PubMed ID: 22359962
[No Abstract] [Full Text] [Related]
13. Alternative Payment Models and Opportunities to Address Disparities in Kidney Disease.
Tummalapalli SL; Ibrahim SA
Am J Kidney Dis; 2021 May; 77(5):769-772. PubMed ID: 33098924
[No Abstract] [Full Text] [Related]
14. Projected impact of the proposed "bundled" ESRD payment system on a small dialysis organization.
Bhat P; Sokolowski W; Bhat JG
Nephrol News Issues; 2009 Jun; 23(7):46, 48-52. PubMed ID: 19585810
[TBL] [Abstract][Full Text] [Related]
15. The social contract and the treatment of permanent kidney failure.
Rettig RA
JAMA; 1996 Apr; 275(14):1123-6. PubMed ID: 8601933
[No Abstract] [Full Text] [Related]
16. Illegal immigration. The impact on renal care.
Chartier K
Nephrol News Issues; 2004 Dec; 18(13):27-8, 30, 32. PubMed ID: 15643821
[No Abstract] [Full Text] [Related]
17. What price success?
Tecnologica; 1996 Nov; ():1-6. PubMed ID: 10179816
[No Abstract] [Full Text] [Related]
18. The QIP: will it improve dialysis care? An overview.
Fishbane S; Miller I; Danko H; Masani N
Nephrol News Issues; 2012 Jan; 26(1):20, 22-4, 26. PubMed ID: 22359961
[TBL] [Abstract][Full Text] [Related]
19. Medicare program; end-stage renal disease prospective payment system. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2010 Aug; 75(155):49029-214. PubMed ID: 20712086
[TBL] [Abstract][Full Text] [Related]
20. Recombinant erythropoietin. The effect of the marketplace on socialized patient care.
Besarab A; Erslev AJ
ASAIO J; 1993; 39(2):85-6. PubMed ID: 8324265
[No Abstract] [Full Text] [Related]
[Next] [New Search]
